Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy : results of a ramdomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

収録刊行物

• J Clin Oncol

  J Clin Oncol 23 1-10, 2005